Journal
CANCER CELL
Volume 14, Issue 4, Pages 285-298Publisher
CELL PRESS
DOI: 10.1016/j.ccr.2008.09.002
Keywords
-
Categories
Funding
- National Institutes of Health [CA109345, CA119785, GM060554, GM062964]
- US Army Medical Research and Material Command [W81XWH-08-1-0478, DAMD17-03-1-0427]
- California Tobacco-Related Diseases Research Program (CTRDRP) [11RT-0081]
- California Breast Cancer Research Program [121B-0168]
- Breast Cancer Foundation [BCTR043351]
Ask authors/readers for more resources
Bcl-2 can be converted into a proapoptotic molecule by nuclear receptor Nur77. However, the development of Bcl-2 converters as anticancer therapeutics has not been explored. Here we report the identification of a Nur77-derived Bcl-2-converting peptide with 9 amino acids (NuBCP-9) and its enantiomer, which induce apoptosis of cancer cells in vitro and in animals. The apoptotic effect of NuBCPs and their activation of Bax are not inhibited but rather potentiated by Bcl-2. NuBCP-9 and its enantiomer bind to the Bcl-2 loop, Which shares the characteristics of structurally adaptable regions with many cancer-associated and signaling proteins. NuBCP-9s act as molecular switches to dislodge the Bcl-2 BH4 domain, exposing its BH3 domain, which in turn blocks the activity of antiapoptotic Bcl-X-L.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available